The invention relates to combinations of an aminosugar and a
beta-2-adrenoceptor agonist, such as salbutamol, for the treatment of
diseases associated with hypersensivity and inflamation, in particular
hypersensivity skin diseases. The aminosugar is preferably a
monosaccharide derivative.